RecruitingNot Applicable

Dominantly Inherited Alzheimer Network (DIAN)

United States, Argentina, Australia700 participantsStarted 2009-01

Plain-language summary

The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Written informed consent obtained from participant and collateral source prior to any study-related procedures. * Aged 18 (inclusive) or older and the child of an affected individual (clinically or by testing) in a pedigree with a known mutation for ADAD. * Cognitively normal to very mild or mild cognitive impairment (CDR score range 0-1.0). Primary enrollment will focus on the recruitment of asymptomatic adult children who are more than 15 years younger than the estimated age of symptom onset. Enrollment of new participants with moderate cognitive impairment is allowed with the prior approval of the DIAN Coordinating Center. * Has two persons who are not their full-blooded siblings who can serve as collateral sources for the study. * Fluent in a language approved by the DIAN Coordinating Center at about the 6th grade level (international equivalent) or above. Exclusion Criteria: * Under age 18 * Medical or psychiatric illness that would interfere in completing initial and follow-up visits * Requires nursing home level care * Has no one who can serve as a study informant

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Positive predictive power of a biomarker or group of biomarkers

Timeframe: Variable follow-up assessment based on age in relation to age at onset of affected parent.

Biomarkers obtained by blood draw, lumbar puncture, MRI, FDG PET, PET amyloid imaging

Timeframe: Variable follow-up assessment based on age in relation to age at onset of affected parent

Clinical markers also examined from clinical interview and cognitive testing

Timeframe: Variable follow-up assessment based on age in relation to age at onset of affected parent

Trial details

NCT IDNCT00869817

SponsorWashington University School of Medicine

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-07

Contact for this trial

Alisha Daniels, MD,MHA

(314) 273-9057

View on ClinicalTrials.gov More Alzheimer's Disease trials

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Positive predictive power of a biomarker or group of biomarkers

Timeframe: Variable follow-up assessment based on age in relation to age at onset of affected parent.

Biomarkers obtained by blood draw, lumbar puncture, MRI, FDG PET, PET amyloid imaging

Timeframe: Variable follow-up assessment based on age in relation to age at onset of affected parent

Clinical markers also examined from clinical interview and cognitive testing

Timeframe: Variable follow-up assessment based on age in relation to age at onset of affected parent